Karsten Schulmann
Overview
Explore the profile of Karsten Schulmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
2130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Volker L, Kaufeld J, Balduin G, Merkel L, Kuhne L, Eichenauer D, et al.
J Thromb Haemost
. 2023 Jan;
21(3):559-572.
PMID: 36696206
Background: The von Willebrand factor-directed nanobody caplacizumab has greatly changed the treatment of immune thrombotic thrombocytopenic purpura (iTTP) in recent years. Data from randomized controlled trials established efficacy and safety....
2.
Vangala D, Ladigan-Badura S, Engel C, Huneburg R, Perne C, Bucksch K, et al.
Int J Cancer
. 2021 Jul;
149(12):2052-2062.
PMID: 34331771
Small bowel cancer (SBC) is the malignancy with the highest standardized incidence ratio in Lynch syndrome (LS) patients. Of all SBCs, about 50% are duodenal cancers (DCs), therefore being accessible...
3.
Noepel-Duennebacke S, Juette H, Schulmann K, Graeven U, Porschen R, Stoehlmacher J, et al.
J Cancer Res Clin Oncol
. 2021 Mar;
147(10):3063-3072.
PMID: 33675399
Introduction: In a retrospective analysis of two randomized phase III trials in mCRC patients treated first line with oxaliplatin, fluoropyrimidine with and without Bevacizumab (the AIO KRK 0207 and R091...
4.
Ladigan-Badura S, Vangala D, Engel C, Bucksch K, Hueneburg R, Perne C, et al.
Int J Cancer
. 2020 Sep;
148(1):106-114.
PMID: 32930401
In our study, we evaluated the effectiveness of upper gastrointestinal (GI) endoscopy as an instrument for early gastric cancer (GC) detection in Lynch syndrome (LS) patients by analyzing data from...
5.
Bucksch K, Zachariae S, Aretz S, Buttner R, Holinski-Feder E, Holzapfel S, et al.
BMC Cancer
. 2020 May;
20(1):460.
PMID: 32448342
Background: Individuals with pathogenic germline variants in DNA mismatch repair (MMR) genes are at increased risk of developing colorectal, endometrial and other cancers (Lynch syndrome, LS). While previous studies have...
6.
Engel C, Ahadova A, Seppala T, Aretz S, Bigirwamungu-Bargeman M, Blaker H, et al.
Gastroenterology
. 2020 Jan;
158(5):1326-1333.
PMID: 31926173
Background & Aims: Lynch syndrome is caused by variants in DNA mismatch repair (MMR) genes and associated with an increased risk of colorectal cancer (CRC). In patients with Lynch syndrome,...
7.
Al-Batran S, Homann N, Pauligk C, Goetze T, Meiler J, Kasper S, et al.
Lancet
. 2019 Apr;
393(10184):1948-1957.
PMID: 30982686
Background: Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin and...
8.
Engel C, Vasen H, Seppala T, Aretz S, Bigirwamungu-Bargeman M, de Boer S, et al.
Gastroenterology
. 2018 Aug;
155(5):1400-1409.e2.
PMID: 30063918
Background & Aims: Patients with Lynch syndrome are at high risk for developing colorectal cancer (CRC). Regular colonoscopic surveillance is recommended, but there is no international consensus on the appropriate...
9.
Schulmann K, Strate K, Pox C, Wieland U, Kreuter A
J Clin Oncol
. 2012 Sep;
30(32):e325-6.
PMID: 23008315
No abstract available.
10.
Reinacher-Schick A, Schulmann K, Modest D, Bruns N, Graeven U, Jaworska M, et al.
BMC Cancer
. 2012 Aug;
12:349.
PMID: 22876876
Background: To evaluate the value of KRAS codon 13 mutations in patients with advanced colorectal cancer (advanced CRC) treated with oxaliplatin and fluoropyrimidines. Methods: Tumor specimens from 201 patients with...